Loading clinical trials...
Loading clinical trials...
An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
Conditions
Interventions
Ixazomib
Bortezomib
+3 more
Locations
23
Japan
Kameda Medical Center
Kamogawa, Chiba, Japan
The Jikei University Kashiwa Hospital
Kashiwa, Chiba, Japan
Ogaki Municipal Hospital
Ōgaki, Gifu, Japan
Gunma University Hospital
Maebashi, Gunma, Japan
Shibukawa Medical Center
Shibukawa, Gunma, Japan
Kobe city Medical Center General Hospital
Kobe, Hyōgo, Japan
Start Date
February 18, 2018
Primary Completion Date
May 28, 2021
Completion Date
May 28, 2021
Last Updated
September 27, 2022
NCT03715478
NCT05893693
NCT05297240
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions